

Susanna Mandruzzato

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2733773/susanna-mandruzzato-publications-by-year.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

74 papers	7,383 citations	35 h-index	84 g-index
84 ext. papers	8,570 ext. citations	8.8 avg, IF	5.46 L-index

#	Paper	IF	Citations
74	Magnetic Resonance Imaging Correlates of Immune Microenvironment in Glioblastoma.. <i>Frontiers in Oncology</i> , 2022 , 12, 823812	5.3	
73	Letter to the Editor Regarding "5-Aminolevulinic Acid False Positives in Cerebral Neuro-Oncology: Not All That Is Fluorescent Is Tumor. A Case-Based Update and Literature Review".. <i>World Neurosurgery</i> , 2022 , 161, 216-217	2.1	
72	Myeloid Diagnostic and Prognostic Markers of Immune Suppression in the Blood of Glioma Patients.. <i>Frontiers in Immunology</i> , 2021 , 12, 809826	8.4	0
71	Sustained Accumulation of Blood-Derived Macrophages in the Immune Microenvironment of Patients with Recurrent Glioblastoma after Therapy.. <i>Cancers</i> , 2021 , 13,	6.6	1
70	Targeting of immunosuppressive myeloid cells from glioblastoma patients by modulation of size and surface charge of lipid nanocapsules. <i>Journal of Nanobiotechnology</i> , 2020 , 18, 31	9.4	16
69	Longitudinal evolution of the immune suppressive glioma microenvironment in different synchronous lesions during treatment. <i>Neuro-Oncology Advances</i> , 2020 , 2, vdz053	0.9	3
68	Human MDSCs derived from the bone marrow maintain their functional ability but have a reduced frequency of induction in the elderly compared to pediatric donors. <i>Immunity and Ageing</i> , 2020 , 17, 27	9.7	4
67	Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study. <i>Cancers</i> , 2020 , 12,	6.6	19
66	Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3 2019 , 7, 255		81
65	The immune suppressive microenvironment of human gliomas depends on the accumulation of bone marrow-derived macrophages in the center of the lesion 2019 , 7, 58		57
64	Role of iron metabolism in the immunosuppression mediated by myeloid cells in glioblastoma patients. <i>Annals of Oncology</i> , 2019 , 30, xi56	10.3	2
63	Methods to Measure MDSC Immune Suppressive Activity In Vitro and In Vivo. <i>Current Protocols in Immunology</i> , 2019 , 124, e61	4	20
62	Immunosuppressive activity of tumor-infiltrating myeloid cells in patients with meningioma. <i>OncImmunology</i> , 2018 , 7, e1440931	7.2	12
61	Induction of immunosuppressive functions and NF- κ B by FLIP in monocytes. <i>Nature Communications</i> , 2018 , 9, 5193	17.4	31
60	In Brief: Myeloid-derived suppressor cells in cancer. <i>Journal of Pathology</i> , 2017 , 242, 7-9	9.4	21
59	Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. <i>Nature Communications</i> , 2016 , 7, 12150	17.4	1388
58	Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab. <i>OncImmunology</i> , 2016 , 5, e1249559	7.2	35

57	Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study. <i>Cancer Immunology, Immunotherapy</i> , 2016 , 65, 161-9	7.4	140
56	Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression. <i>Oncotarget</i> , 2016 , 7, 1168-84	3.3	82
55	Low dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapy. <i>Biomaterials</i> , 2016 , 96, 47-62	15.6	98
54	Complexity and challenges in defining myeloid-derived suppressor cells. <i>Cytometry Part B - Clinical Cytometry</i> , 2015 , 88, 77-91	3.4	86
53	Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. <i>Journal of Clinical Investigation</i> , 2015 , 125, 3365-76	15.9	351
52	Human miRNome profiling in colorectal cancer and liver metastasis development. <i>Genomics Data</i> , 2014 , 2, 184-8		6
51	Myeloid-derived suppressor cell heterogeneity in human cancers. <i>Annals of the New York Academy of Sciences</i> , 2014 , 1319, 47-65	6.5	280
50	Human fibrocytic myeloid-derived suppressor cells express IDO and promote tolerance via Treg-cell expansion. <i>European Journal of Immunology</i> , 2014 , 44, 3307-19	6.1	81
49	An integrative framework identifies alternative splicing events in colorectal cancer development. <i>Molecular Oncology</i> , 2014 , 8, 129-41	7.9	34
48	Gene expression profiling of human fibrocytic myeloid-derived suppressor cells (f-MDSCs). <i>Genomics Data</i> , 2014 , 2, 389-92		8
47	Complexity and challenges in defining myeloid-derived suppressor cells. <i>Cytometry Part B - Clinical Cytometry</i> , 2014 ,	3.4	82
46	Circulating miR-182 is a biomarker of colorectal adenocarcinoma progression. <i>Oncotarget</i> , 2014 , 5, 6611-33	3.3	49
45	Arginase, Nitric Oxide Synthase, and Novel Inhibitors of L-arginine Metabolism in Immune Modulation 2013 , 597-634		2
44	Impact of microRNAs on regulatory networks and pathways in human colorectal carcinogenesis and development of metastasis. <i>BMC Genomics</i> , 2013 , 14, 589	4.5	120
43	Metastatic lesions with and without interleukin-18-dependent genes in advanced-stage melanoma patients. <i>American Journal of Pathology</i> , 2013 , 183, 69-82	5.8	11
42	Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. <i>Cell Reports</i> , 2012 , 2, 628-39	10.6	152
41	Highlights on molecular mechanisms of MDSC-mediated immune suppression: paving the way for new working hypotheses. <i>Immunological Investigations</i> , 2012 , 41, 722-37	2.9	29
40	Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. <i>Nature Medicine</i> , 2012 , 18, 1254-61	50.5	636

39	Myeloid-derived suppressor cells in cancer patients: a clinical perspective. <i>Journal of Immunotherapy</i> , 2012 , 35, 107-15	5	176
38	Antigen specificity of immune suppression by myeloid-derived suppressor cells. <i>Journal of Leukocyte Biology</i> , 2011 , 90, 31-6	6.5	67
37	A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. <i>Blood</i> , 2011 , 118, 2254-65	2.2	280
36	Myeloid cell diversification and complexity: an old concept with new turns in oncology. <i>Cancer and Metastasis Reviews</i> , 2011 , 30, 27-43	9.6	34
35	Exocytosis of azurophil and arginase 1-containing granules by activated polymorphonuclear neutrophils is required to inhibit T lymphocyte proliferation. <i>Journal of Leukocyte Biology</i> , 2011 , 89, 721-7	6.5	86
34	Myeloid-derived suppressor cell heterogeneity and subset definition. <i>Current Opinion in Immunology</i> , 2010 , 22, 238-44	7.8	520
33	Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. <i>Immunity</i> , 2010 , 32, 790-802	32.3	644
32	Reprogramming T lymphocytes for melanoma adoptive immunotherapy by T-cell receptor gene transfer with lentiviral vectors. <i>Cancer Research</i> , 2009 , 69, 9385-94	10.1	47
31	Differential expression of constitutive and inducible proteasome subunits in human monocyte-derived DC differentiated in the presence of IFN-alpha or IL-4. <i>European Journal of Immunology</i> , 2009 , 39, 56-66	6.1	23
30	IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. <i>Journal of Immunology</i> , 2009 , 182, 6562-8	5.3	263
29	Identification of genes selectively regulated by IFNs in endothelial cells. <i>Journal of Immunology</i> , 2007 , 178, 1122-35	5.3	123
28	Arginase, Nitric Oxide Synthase, and Novel Inhibitors of L-Arginine Metabolism in Immune Modulation 2007 , 369-399		
27	Technological platforms for microarray gene expression profiling. <i>Advances in Experimental Medicine and Biology</i> , 2007 , 593, 12-8	3.6	11
26	Survivin in esophageal cancer: An accurate prognostic marker for squamous cell carcinoma but not adenocarcinoma. <i>International Journal of Cancer</i> , 2006 , 119, 1717-22	7.5	50
25	Leukocyte infiltration in cancer creates an unfavorable environment for antitumor immune responses: a novel target for therapeutic intervention. <i>Immunological Investigations</i> , 2006 , 35, 327-57	2.9	32
24	Common cancer biomarkers. <i>Cancer Research</i> , 2006 , 66, 2953-61	10.1	84
23	A gene expression signature associated with survival in metastatic melanoma. <i>Journal of Translational Medicine</i> , 2006 , 4, 50	8.5	82
22	Cancer rejection by the immune system: Forcing the check-points of tumor immune escape. <i>Drug Discovery Today Disease Mechanisms</i> , 2005 , 2, 191-197		1

21	Cancer vaccines: pessimism in check. <i>Nature Medicine</i> , 2004 , 10, 1278-9; author reply 1279-80	50.5	40
20	Melanoma-restricted genes. <i>Journal of Translational Medicine</i> , 2004 , 2, 34	8.5	40
19	Part I: Vaccines for solid tumours. <i>Lancet Oncology, The</i> , 2004 , 5, 681-9	21.7	180
18	Part II: Vaccines for haematological malignant disorders. <i>Lancet Oncology, The</i> , 2004 , 5, 727-37	21.7	31
17	Large and dissimilar repertoire of Melan-A/MART-1-specific CTL in metastatic lesions and blood of a melanoma patient. <i>Journal of Immunology</i> , 2002 , 169, 4017-24	5.3	36
16	MAGE, BAGE, and GAGE gene expression in patients with esophageal squamous cell carcinoma and adenocarcinoma of the gastric cardia. <i>Cancer</i> , 2001 , 91, 1882-1888	6.4	42
15	MAGE, BAGE and GAGE gene expression in human rhabdomyosarcomas. <i>International Journal of Cancer</i> , 2001 , 93, 85-90	7.5	34
14	A human CTL recognizes a caspase-8-derived peptide on autologous HLA-B*3503 molecules and two unrelated peptides on allogeneic HLA-B*3501 molecules. <i>Journal of Immunology</i> , 2000 , 164, 4130-4	5.3	16
13	Molecular cloning and identification of murine caspase-8. <i>Journal of Molecular Biology</i> , 1998 , 284, 1017-26	26.5	33
12	A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. <i>Journal of Experimental Medicine</i> , 1997 , 186, 785-93	16.6	284
11	Protein tyrosine kinases and phosphatases control apoptosis induced by extracellular adenosine 5Rtriphosphate. <i>Biochemical and Biophysical Research Communications</i> , 1996 , 218, 344-51	3.4	34
10	CD45 regulates apoptosis induced by extracellular adenosine triphosphate and cytotoxic T lymphocytes. <i>Biochemical and Biophysical Research Communications</i> , 1996 , 226, 769-76	3.4	12
9	A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3. <i>Immunogenetics</i> , 1996 , 43, 377-83	3.2	90
8	Anti-L-selectin monoclonal antibody treatment in mice enhances tumor growth by preventing CTL sensitization in peripheral lymph nodes draining the tumor area. <i>International Journal of Cancer</i> , 1996 , 65, 847-51	7.5	10
7	A peptide encoded by the human MAGE3 gene and presented by HLA-1344 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3 1996 , 43, 377		6
6	Role of anti-LFA-1 and anti-ICAM-1 combined MAb treatment in the rejection of tumors induced by Moloney murine sarcoma virus (M-MSV). <i>International Journal of Cancer</i> , 1995 , 61, 355-62	7.5	7
5	Inhibition of protein tyrosine phosphorylation prevents T-cell-mediated cytotoxicity. <i>Cellular Immunology</i> , 1994 , 159, 294-305	4.4	10
4	Synergistic effect of extracellular adenosine 5Rtriphosphate and tumor necrosis factor on DNA degradation. <i>Cellular Immunology</i> , 1993 , 152, 110-9	4.4	9

- 3 Therapeutical effect of 4Rdeoxy-4Riododoxorubicin-loaded LAK cells in mice bearing lung metastases. *Pharmacological Research*, **1992**, 26 Suppl 2, 124-5 10.2 1
- 2 Inhibition of CTL-line lysis after gangliosides treatment. *Pharmacological Research*, **1992**, 26 Suppl 2, 190-1 10.2
- 1 Antitumour efficacy of lymphokine-activated killer cells loaded with ricin against experimentally induced lung metastases. *Cancer Immunology, Immunotherapy*, **1992**, 35, 27-32 7.4 6